Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials

December 30, 2024
Bristol Myers Squibb (BMY) recently announced positive topline results from its Phase 3 trials evaluating Sotyktu deucravacitinib in adults with psoriatic arthritis.
The trials showed promising results, meeting key endpoints and demonstrating the potential of Sotyktu as a treatment option for this condition. Psoriatic arthritis is a chronic inflammatory disease that affects both the skin and joints, causing pain and stiffness. This news highlights Bristol Myers Squibb's commitment to developing innovative therapies to improve the lives of patients and further strengthens its position in the pharmaceutical industry. Investors interested in the stock movement of BMY may consider seeking professional guidance from Stocks Prognosis to make informed decisions.

Find out how the BRISTOL-MYERS SQUIBB COMPANY rate is expected to change

Get Forecast for BMY

Investor opinions & comments:

I'm glad to hear that the Phase 3 trials for Sotyktu deucravacitinib were successful in treating psoriatic arthritis. It's always encouraging to see advancements in medical research that could potentially improve the quality of life for patients
— from ProfitPiper at 12-31-2024 16:51
While the results are promising, I wonder about the long-term effects and potential side effects of Sotyktu deucravacitinib. More research and studies should be conducted before considering it as a viable treatment option for psoriatic arthritis
— from JacobYoung at 12-30-2024 17:27
This is exciting news! It's great to see Bristol Myers Squibb making progress in finding new treatments for psoriatic arthritis. Can't wait to see how Sotyktu deucravacitinib develops further
— from RobertWhite at 12-30-2024 03:29
If you want to leave a comment, then you need Login or Register





Other news for BMY

BMYMarch 21, 2025Market Update: Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note  ~1 min.

Bristol Myers Squibb (BMY) has seen a recent upswing in its stock price, but it still lags behind the overall market. Here are some key facts to consider about the company....

BMYMarch 20, 2025Is Bristol-Myers Squibb the Most Undervalued Biotech Company?  ~2 min.

Recently, the European Commission (EC) has given its approval to Breyanzi, a novel treatment developed by Bristol-Myers Squibb (BMS) for Non-Hodgkin's Lymphoma (NHL)....

BMYMarch 19, 2025Positive Development for Bristol-Myers Squibb Company's Breyanzi NHL Treatment  ~1 min.

Bristol-Myers Squibb Company's groundbreaking NHL treatment, Breyanzi, has received approval from the European Commission (EC) for its use in patients....

BMYMarch 18, 2025Is Bristol-Myers Squibb Company BMY the Best Pharma Stock to Buy According to Hedge Funds  ~1 min.

Bristol-Myers Squibb Company (BMY) has gained the attention of hedge funds as the best pharmaceutical stock to invest in....

BMYMarch 17, 2025Why Bristol-Myers Squibb Company BMY Went Down On Friday  ~1 min.

Bristol-Myers Squibb Company (BMY) experienced a decline in their stock price on Friday. The decrease can be attributed to factors such as market volatility and investor sentiment....



Related news

BMYDecember 26, 2024Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock  ~1 min.

Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have shown promising outcomes, with the drug meeting key endpoints and demonstrating effectiveness in treating the condition. Psoriatic arthritis is a chronic ...

LLYFebruary 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development  ~1 min.

Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....

BMYDecember 29, 2024Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment  ~1 min.

Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors ...

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....

REGNJanuary 5, 2025Regeneron Pharmaceuticals: A Strong Performer with Promising Financials  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....